RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Bengbu Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05192798, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 80 years; sex: women only

    Registered eligibility fields

  2. For subjects who have previously undergone adjuvant/neoadjuvant therapy, the time from the end of the last chemotherapy (including taxanes) to randomization should be ≥12 months; The time from the end of radical radiotherapy to randomization should be ≥6 months.

    Inclusion criterion 7

  3. Eastern Cooperative Oncology Group performance status (ECOG PS) : 0-2;

    Inclusion criterion 5

  4. Absolute neutrophil count ≥ 1.5 x 10\^9 / L;

    Inclusion criterion 9

    Platelet count ≥ 100 x 10\^9 / L;

    Inclusion criterion 10

    Hemoglobin ≥ 90 g/L;

    Inclusion criterion 11

    Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤2.5 × upper limit of normal (ULN); ALT and AST≤5 × ULN if liver metastasis is present;

    Inclusion criterion 12

    Creatinine clearance rate(Ccr) ≥60 mL/min according to the Cockcroft-Gault formula;

    Inclusion criterion 13

    Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 × ULN, and international normalized ratio (INR)≤1.5 × ULN.

    Inclusion criterion 14

  5. Presence of at least one measurable lesion according to RECIST 1.1;

    Inclusion criterion 3

  6. Previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix;

    Exclusion criterion 11

  7. Patients who are pregnant or breast-feeding;

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05192798, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Female patients aged ≥18 years and ≤80 years;
  • Patients with recurrent or metastatic triple negative breast cancer confirmed by histopathology and imaging;
  • Presence of at least one measurable lesion according to RECIST 1.1;
  • Expected survival ≥3 months;
  • Eastern Cooperative Oncology Group performance status (ECOG PS) : 0-2;
  • Patients who have not previously received antitumor systemic therapy for the stage of relapse or metastasis;
  • For subjects who have previously undergone adjuvant/neoadjuvant therapy, the time from the end of the last chemotherapy (including taxanes) to randomization should be ≥12 months; The time from the end of radical radiotherapy to randomization should be ≥6 months.
  • Major organs show good function, and the relevant examination indexes within 7 days prior to randomization meet the following requirements:
  • Absolute neutrophil count ≥ 1.5 x 10\^9 / L;
  • Platelet count ≥ 100 x 10\^9 / L;
  • Hemoglobin ≥ 90 g/L;
  • Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤2.5 × upper limit of normal (ULN); ALT and AST≤5 × ULN if liver metastasis is present;
  • Creatinine clearance rate(Ccr) ≥60 mL/min according to the Cockcroft-Gault formula;
  • Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 × ULN, and international normalized ratio (INR)≤1.5 × ULN.
  • Subjects voluntarily agree to participate in the study and sign informed consent, with good compliance and being accessible for treatment and follow-up.

Exclusion Criteria:

  • Patients who are pregnant or breast-feeding;
  • Patients with multiple factors affecting oral medication (such as swallow inability, chronic diarrhea and intestinal obstruction);
  • Known hypersensitivity reaction to any of the components of the treatment;
  • Peripheral neuropathy ≥ grade 2, whatever the cause;
  • Serious other diseases as infections (hepatitis B, C and HIV), recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrhythmias or on screening, any of the following cardiac parameters: bradycardia (heart rate <50 at rest) or heart rate-corrected QT interval via Fridericia (QTcF) ≥470 msec.
  • Patients with urinary protein ≥++ indicated by routine urine examination, and the 24-hour urine protein level was confirmed to be > 1.0g;
  • Patients with imaging showing that the tumor has invaded important blood vessels or the investigator judges that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during the follow-up study;
  • Patients who have experienced arteriovenous or venous thrombosis events within 6 months prior to randomization, such as cerebrovascular accident (including temporary ischemic attack), deep vein thrombosis and pulmonary embolism;
  • Any bleeding or bleeding event ≥grade 3 within 4 weeks prior to the first dose of therapy; Or the presence of unhealed wounds, fractures, gastrointestinal diseases such as gastric and duodenal active ulcers, ulcerative colitis, or active bleeding of unresected tumors, or other conditions that may cause gastrointestinal bleeding or perforation as determined by the investigator;
  • Uncontrolled effusion management (pleural effusion, pericardial effusion, or ascites) which requires frequent drainage procedures;
  • Previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix;
  • Participants in clinical trials of other antitumor drugs within 4 weeks prior to randomization;
  • Other circumstances in which participation in the study would be inappropriate as determined by the investigator.

Quoted from ClinicalTrials.gov, NCT05192798, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05192798, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05192798